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Abstract
Background: Drug repurposing, the process of identifying additional therapeutic uses for existing drugs, has
attracted increasing attention from both the pharmaceutical industry and the research community. Many
existing computational drug repurposing methods rely on preclinical data (e.g., chemical structures, drug
targets), resulting in translational problems for clinical trials.
Methods: In this study, we propose a clinical connectivity map framework for drug repurposing by leveraging
laboratory tests to analyze complementarity between drugs and diseases. We establish clinical drug effect
vectors (i.e., drug-laboratory test associations) by applying a continuous self-controlled case series model on a
longitudinal electronic health record data. We establish clinical disease sign vectors (i.e., disease-laboratory test
associations) by applying a Wilcoxon rank sum test on a large-scale national survey data. Finally, we compute
a repurposing possibility score for each drug-disease pair by applying a dot product-based scoring function on
clinical disease sign vectors and clinical drug effect vectors.
Results: We comprehensively evaluate 392 drugs for 6 important chronic diseases (include asthma, coronary
heart disease, congestive heart failure, heart attack, type 2 diabetes, and stroke). We discover not only known
associations between diseases and drugs, but also many hidden drug-disease associations. For example,
clopidogrel and alendronate may be repurposed as candidate drugs for diabetes and cardiovascular diseases
respectively. Moreover, we are able to explain the predicted drug-disease associations via the corresponding
complementarity between laboratory tests of drug effect vectors and disease sign vectors.
Conclusion: The proposed clinical connectivity map framework uses laboratory tests from electronic clinical
information to bridge drugs and diseases, which is explainable and has better translational power than existing
computational methods. Experimental results demonstrate the effectiveness of the proposed framework and
suggest that our method could help identify drug repurposing opportunities, which will benefit patients by
offering more effective and safer treatments.
Availability: The code for this paper is available at: https://github.com/HoytWen/CCMDR
Keywords: Drug Repurposing; Connectivity Map; Electronic Health Record; National Health and Nutrition
Examination Survey
Introduction
Traditional de novo drug discovery is a long and com-
plicated process [1, 2], which usually takes more than
15 years [3], and costs 800 million to 1 billion US dol-
lars [4] to develop a new drug. Drug repurposing, inves-
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tigation of potential additional uses for existing drugs,
is becoming an appealing research field given its po-
tential in lowering overall costs and shortening drug
development timelines [5].
There has been a surge of computational methods
proposed for drug repurposing in recent years, which
can be roughly classified into two categories based on
different data sources: preclinical data-based and clin-
ical data-based. Preclinical data-based methods often
build machine learning models based on preclinical
data, such as drug chemical structure, protein tar-
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gets and gene expression information, to identify po-
tential drug-disease associations. For example, Keiser
et al. [6] use drug structural similarity as the mea-
surements to find the drugs with similar effects. Lamb
et al. [7, 8] raise the connectivity map (CMap) ap-
proach for drug repurposing by using gene expression
data, which is based on molecular activity. Luo et al.
[9] develop a server named DPDR-CPI which predicts
the new indications of existing drugs by analyzing the
chemical-protein interactome (CPI) profile. Some re-
searchers also tried to construct computational frame-
works that integrated several kinds of data sources and
even disease similarity measurement profiles to make
better predictions. PreDR model proposed by Wang
et al. [10] integrated drug structure, drug target, side-
effects and disease phenotype data to find the novel
drug indications. Zhang et al. [11] raised a similar-
ity constrained matrix factorization method to predict
drug-disease association based on known drug-disease
associations, drug features and disease semantic infor-
mation. However, all of these methods rely heavily on
preclinical information to make predictions. This will
cause a large translation gap when we apply the drugs
on humans. It is estimated that of all compounds ef-
fective in cell assays, only 30% of them could work in
animals and only 5% of them could work in humans
[12].
Compared with preclinical data, clinical data provide
more applicable and reliable data sources for drug re-
purposing as clinical information (e.g., laboratory test
results) may be seen as valuable read-outs of drug ef-
fects directly on human bodies. It is directly observed
form patients, so there is no need to consider about the
translational problems. Many computational frame-
works based on clinical information has been raised
due to the large amount of available electronica clini-
cal data. Jung et al. [13] find the connection between
drugs and diseases in clinical diagnose notes by liter-
ature mining, but it does not include any other struc-
tured data, like laboratory test results. Jang et al. [14]
propose a framework that use laboratory test results
to reflect the influence of drugs and diseases on hu-
man physiological activities, and the method they use
to establish drug effects is counting co-occurrence be-
tween drug and laboratory tests. However, it is not
efficient enough to dig the hidden relation between
drugs and laboratory tests, especially when we have
a large dataset and include many laboratory and ex-
isting drugs in our experiment. Kuang et al. [15] and
Ghalwash et al. [16] raised more advanced methods
to compute the influence of drugs on laboratory tests,
however, they reflect the effect of drugs on single labo-
ratory (e.g., blood sugar level), which it is not enough
to represent the state of the complex human system.
It would be more efficient and accurate if we build an
electronic clinical information-based drug repurposing
framework and implement it by more efficient statisti-
cal analysis methods designed for large datasets. Dur-
ing this process, we will include as many laboratory
tests as we can in our experiment to completely rep-
resent the state of human biological system. The idea
of CMap raised by Lamb et al. [7, 8] which uses gene
expression values to bridge drugs and diseases, directly
inspires us to formulate and leverage all the laboratory
tests involved in our experiment to build associations
between drugs and diseases from clinical perspective.
In this paper, we propose a clinical connectivity map
framework for drug repurposing (CCMDR) by lever-
aging laboratory tests to analyze the influence of drugs
and diseases on the human biological system. Specif-
ically, we first establish clinical disease sign vectors
(i.e., disease-laboratory test associations) by applying
a Wilcoxon rank sum test on a large-scale national
survey data. We then establish clinical drug effect vec-
tors (i.e., drug-laboratory test associations) by apply-
ing a continuous self-controlled case series model on a
longitudinal electronic health record data. Finally, we
compute a repurposing possibility score for each drug-
disease pair by applying a dot product-based scoring
function on clinical disease sign vectors and clinical
drug effect vectors. Experimental results show that our
method can not only retrieve the known drug-disease
associations in high accuracy but also can find poten-
tial indications, which can be verified from medical
literature. For example, clopidogrel and alendronate
may be repurposed as candidate drugs for diabetes
and cardiovascular diseases respectively. Moreover, we
can explain the predicted drug-disease associations via
the corresponding complementarity between labora-
tory tests of drug effect vectors and disease sign vec-
tors. So, it is suggested that our method can be poten-
tially used in drug repurposing tasks.
In brief, the contribution of the paper can be sum-
marized as below:
• We propose a clinical connectivity mapping frame-
work for drug repurposing. The new framework
solely based on the clinical patient data, thus with
less translational problems.
• We evaluate our framework for 392 drugs on 6
important chronic diseases (include asthma, coro-
nary heart disease, congestive heart failure, heart
attack, type 2 diabetes, and stroke). Experimental
results show that our method achieves high accu-
racy in retrieving the known indications of drugs.
• We study the predicted drug repurposing candi-
dates via the corresponding complementarity be-
tween laboratory tests of drug effect vectors and
disease sign vectors. Case studies with literature
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support show the potential of our method to dis-
cover previously unknown indications of existing
drugs.
Methodology
Dataset and Data Preprocess
We use the questionnaire and laboratory test results
from the National Health and Nutrition Examination
Survey (NHANES) [17] to establish the clinical dis-
ease sign vectors. According to the questionnaire sur-
vey (e.g., ”Has been diagnosed with type 2 diabetes?”),
individual samples are divided into disease group (who
answered ”yes”) and healthy group (who answered
”no”). Next, we perform the statistical analysis to
identify those disease-related clinical variables from
collected laboratory test results in NHANES data. We
extract 87,464 individual samples, 986 numerical clini-
cal variables and more than 30 disease conditions from
NHANES data range from 1999 to 2016. Here, we only
consider the disease conditions with more than 1000
individual samples, which results in 6 unique diseases
(i.e., asthma, coronary heart disease, congestive heart
failure, heart attack, type 2 diabetes and stroke).
We use the prescription and laboratory test re-
sult histories of patients in Electronic Health Record
(EHR) to establish the clinical drug effect vectors. We
transform the prescription records of patients into ma-
trixes based on medication use situations. To study
the associations between prescribed drugs and labora-
tory test results, we apply a continuous self-controlled
case series model [15] to analyze the effects of a drug
on the laboratory test results. Our proprietary EHRs
contain comprehensive health records of more than
300 thousand patients over four years. We only con-
sider patients with complete records (i.e., having both
prescription and its corresponding laboratory test re-
sults), which results in 91,934 patients, 1,344 kinds
of treatments and 65 kinds of laboratory tests. After
excluding those prescriptions with less than 1000 pa-
tients, we obtain 392 unique prescribed drugs.
We bridge the drug and disease using the laboratory
test results obtained from each side. Since the labora-
tory test results are from different data resources (i.e.,
national survey data and electronic health records),
we need to standardize those laboratory tests for fur-
ther analysis. The laboratory tests that appear in both
datasets are included and mapped to a standard list
with consistent names. Also, the non-numerical labo-
ratory tests are excluded. Finally, we obtain 35 labo-
ratory tests considered as clinical variables. The full
list of the 35 clinical variables can be found in Table
S1. Our inference of a drug-disease pair is based on
the complementary and adverse effects that each drug
candidate and disease condition has on the 35 clinical
variables.
Clinical Disease Sign Vector
We extract 6 disease conditions and 35 clinical vari-
ables from NHANES after preprocessing to establish
the clinical disease sign vector. The dimension of each
disease sign vector is 1 × 35. There are three types of
relations between a disease and clinical vectors (i.e.,
”Up”, ”Down” and ”No”), which represents increas-
ing, decreasing and not significantly changing of lab-
oratory tests level, respectively. As mentioned above,
the combined data is divided into disease group and
control group according to the questionnaire data, we
apply Wilcoxon rank sum test (a.k.a., Mann Whit-
ney U test) on two groups to calculate the p-value for
each clinical variable. To get the p-value, we combine
the values of the two groups and rank them. Then we
calculate two statistical values U1 and U2, which are
defined as follows:
U1 = R1 − n1(n1+1)2
U2 = R2 − n2(n2+1)2
(1)
where n1 and n2 are the sample sizes of the two groups,
R1 and R2 are the sum of the ranks in the two groups,
respectively. The smaller value of U1 and U2 is used
to consult the Mann-Whitney significance table. Cer-
tain p-value cut-off is used to examine whether the
value change is significant or not [18]. In our work, the
p-value threshold is set to be 0.05. Only the clinical
variables satisfy the condition that p-values are less
than 0.05 can be regarded as significant clinical vari-
ables concerning the disease. We consult the Mann-
Whitney table of α = 0.05. If the smaller value of U1
and U2 is larger than the value given in the table, the
null hypothesis is true otherwise false. Then we assign
relation direction to this clinical variable by comparing
the average clinical variable value of the disease group
and control group. Up relation (”↑”) indicates a signifi-
cant value increase in the disease group compared with
the control group, while down relation (”↓”) means
the laboratory test value of the disease group is signif-
icantly lower than that of the control group, no rela-
tion (”-”) indicate the laboratory test level will not be
significantly influenced by the disease.
Clinical Drug Effect Vector
To establish clinical drug effect vectors, we extract 392
drugs and 35 clinical variables from EHR data. The
clinical variables used here are the same as ones in
establishing the disease sign vectors. So, the dimen-
sion of each drug effect vector is 1 × 35. We need to
consider the prescription records of patients and their
corresponding laboratory test results records simulta-
neously, and the EHR dataset we use is a large dataset
that includes millions of records. So, we need to find a
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Figure 1 This figure presents the pipeline of our framework. The framework contains three main components: (1) establishing
clinical drug effect vectors by applying a continuous self-controlled case series model on a longitudinal electronic health record data
(EHR), (2) establishing clinical disease sign vectors by applying a Wilcoxon rank sum test on a large-scale national survey data
(NHANES), (3) computing repurposing possibility score for each drug-disease pair by applying a dot product-based scoring function
on clinical disease sign vectors and clinical drug effect vectors. We do a terminology mapping before we establish the clinical drug
effect vectors and clinical disease sign vectors to make sure each clinical vector includes the same laboratory tests. There are three
kinds of relation types in the clinical vectors (”Up”, ”Down”, ”No”), which represent increasing, decreasing and not significantly
changing laboratory tests level, respectively.
way to analyze the high-dimensional longitudinal data.
In our work, we adopt the continuous self-controlled
case Series (CSCCS) model proposed by Kuang et al.
[15], it is a lasso regression analysis model designed to
do the data analytical work for EHR dataset.
Assuming there are N patients with a specific kind
of clinical variable measurement and M kinds of drugs
in EHR dataset. Continuous variable yij , where i ∈
{1, 2, · · · , N}, j ∈ {1, 2, · · · , Ji}, indicates the value
of jth clinical variable measurement taken among a
total number of Ji measurements for the ith patient,
while binary variable xijm, where i ∈ {1, 2, · · · , N},
j ∈ {1, 2, · · · , Ji}, m ∈ {1, 2, · · · ,M}, are used to in-
dicated the drug whether ith patient are exposed to the
mth drug when the jth clinical variable measurement
is taken. 0 represents no and 1 represents yes.
yij is regard as the output variables when we fit the
structured data into the linear regression model, so we
have:
yij |xij = αi + β>xij + ij , ij iid∼ N
(
0, σ2
)
(2)
β =
[
β1 β2 · · · βM
]>
,
xij =
[
xij1 xij2 · · · xijM
]>
αi in equation (2) represents the average baseline
level of yij on ith patient. That means it is independent
of the date the measurement was taken and drugs the
patient used when the measurement was taken. Each
patient has an individual baseline value. ij here is
an independent and identically distributed Gaussian
noises with zero means and fixed but unknown vari-
ance σ2. Then the linear model can be easily converted
to a least square problem as follows:
arg min
α,β
L(α,β) = arg min
α,β
1
2
∥∥∥∥y − [Z X] [αβ
]∥∥∥∥2
2
(3)
where
α =
[
α1 α2 · · · αN
]>
, Z = diag
(
11, · · · ,1N
)
,
y =
[
y11 · · · y1J1 · · · yN1 · · · yNJN
]>
,
X =
[
x11 · · · x1J1 · · · xN1 · · · xNJN
]>
where Z is a block diagonal matrix and 1i is a Ji × 1
vector in which all the components are 1. By solving
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this problem, we can get the optimized parameter β,
which is also the interest of our task. β is a 1×M pa-
rameter vector, parameter βm in β indicates the effect
of mth drug on the output variable y. The optimized
parameter we get with the CSCCS model is numer-
ical. Positive and negative parameters in this vector
represent the corresponding drugs that may increase
and decrease the level of output variable respectively,
while 0 indicates the corresponding drugs do not influ-
ence it. In the CSCCS model, parameter α is regarded
as a nuisance parameter, our interest is parameter β
so we do not need to care the value of α. To eliminate
the effect of α, [15] consider:
∂L(α,β)
∂α
= 0⇒ α =
(
Z>Z
)−1
Z>(y −Xβ) = y −Xβ (4)
Where y is a N × 1 vector which includes the
average value of clinical value among N patients,
yi =
1
Ji
∑Ji
j=1 yij . X is a N ×M matrix and Xi =
1
Ji
∑Ji
j=1 x
>
ij . So, the expression of CSCCS model be-
low, which is free of α, is derived by substituting equa-
tion (4) into equation (3):
arg min
β
1
2
‖y −Zy − (X −ZX)β‖22 (5)
When we apply the CSCCS model on the high-
dimensional longitudinal EHR data, we will add a L1
penalty term because there is an assumption that the
level of clinical variables will only be significantly influ-
enced by a small portion of drugs. The L1 penalization
drives most components of β to zero or closed to zero
[19]. In other words, we simply want to know the drugs
which are most correlated to the level change of clin-
ical variables. So the final expression of the CSCCS
model we apply to this problem is:
arg min
β
1
2
‖y −Zy − (X −ZX)β‖22 + λ‖β‖1 (6)
where λ > 0, λ decides the sparsity of optimized result
so we need to tune this parameter to get a final result
with proper sparsity level.
In order to further filter out the drugs which do not
have a significant effect on clinical variables, our imple-
mentation also returns the p-value of each component
in β. We apply the same p-value cut-off strategy on the
optimized result. Parameters with a p-value greater
than 0.05 in β are regarded as insignificant effect and
we assume their corresponding drugs are uncorrelated
with clinical variable level change. The significant ef-
fects can be divided into increasing or decreasing ef-
fect based on the coefficient value is positive or neg-
ative. Then we assign each drug-clinical variable pair
up (”↑”), down (”↓”) and no (”-”) relation type just
like clinical disease sign vectors.
Scoring Function
After we establish the clinical vectors for each drug-
disease pair, we need to define a scoring function to cal-
culate the repurposing possibility score for each drug-
disease pair. The inference for each drug-disease pair
is based on complementary and adverse effects. Specif-
ically, complementary effect refers to the opposed re-
lation type between a clinical disease sign vector and
clinical drug effect vector on the same clinical vari-
ables, while adverse effect refers to the same relation
type between a clinical disease sign vector and clinical
drug effect vector on the same clinical variables. The
complementary relation direction between the two vec-
tors will increase the final repurposing possibility score
of a drug-disease pair while adverse relation direction
will decrease it. Here, we use a dot product-based scor-
ing function to consider both complementary and ad-
verse effects of a drug candidate on a disease. The scor-
ing function can be written as follow:
TSdisease−drug = −CVDrug · CVDisease (7)
where CVDrug is the clinical drug effect vector, and
CVDisease is the clinical disease sign vector. We trans-
form the 3 kinds of relation type in clinical vectors
(”↑”, ”↓” and ”-”) into numerical values (1.0, -1.0, 0.0)
for the convenience of calculation. To rank the drugs
in descending order and emphasize the most power-
ful drug candidates predicted by our model, we add a
minus sign before the product of the two vectors. So,
the positive result calculated by this scoring function
means there are more complementary relation direc-
tions than adverse relation directions between a drug
candidate and a disease, while negative results indicate
more adverse relation directions between this pair.
Results and Discussion
Evaluation Metrics
After we calculate the repurposing possibility score of
each drug-disease pair, we need to prove that the score
is qualified enough to serve as a metric to show whether
a drug candidate is likely to be the potential treatment
or not. The final drug candidate list is sorted by the
repurposing possibility score in a descending order for
the convenience of validation. The validation data we
use comes from Side Effect Resource(SIDER) [20]. It
contains drugs with indications or side-effects for many
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kinds of disease conditions. We take it for ground truth
to testify whether our method can retrieve known in-
dications of drugs. The hypothesis is that drug can-
didates with higher repurposing possibility score are
more likely to be the treatment of the disease, which
means most of the top-ranking drugs can be found in
the drugs with indication and most of the bottom rank-
ing drugs can be found in the drugs with side-effects
provided by SIDER. In this case, those drugs can not
be found in the validation data but still predicted with
high repurposing possibility score by our model could
be served as a potential treatment of the disease. So
we need to use some evaluation metrics to test whether
the known drug-diseases pairs are enriched at the top
of our prediction list. We will use two kinds of evalua-
tion metrics to validate our prediction.
Precision at K
The First kind of evaluation metric is precision at K.
The top K precision value is the ratio of known treat-
ment for a disease among the top K drug candidates
for the disease predicted by our framework. For each
disease, we rank the drugs using the calculated repur-
posing possibility score. Then we compute the preci-
sion atK (K ∈ {5, 10, 15, 20}) of each disease using the
top-ranked K drugs (e.g., precision at 10 corresponds
to the proportion of correct retrieved drugs among the
top 10 ranked drugs).
Fold-Enrichment Test
Another evaluation metric to access whether our re-
purposing possibility score is correlated with the like-
lihood that disease-drug pair occurs or not is the fold-
enrichment (FE) test. FE score can be defined by the
following formula:
FE Score =
(n/m)
(N/M)
(8)
where M is the number of all the mapped drugs and
N is the number of drugs in the gold-standard dataset
corresponding to each kind of disease condition. We
will divide all the mapped drugs evenly into several
groups according to their repurposing possibility score.
So, m is the total number of drugs in one group and n
is the number of drugs involved in the gold-standard
dataset within the group. FE test can demonstrate the
enrichment of known disease-drug pair (we assume the
drug-disease pairs in SIDER is ground truth) within
different score ranges. Our prediction can be proved
to be reasonable if the FE test score is positively cor-
related with the repurposing possibility score. There
are 392 drug-disease pairs for each kind of disease con-
dition in our experiment, and all of them are ranked by
repurposing possibility score and binned into groups of
80 pairs (the last group contains 72 drug-disease pairs).
The scoring function is reasonable if the FE score is
decreasing with the ascending order of the 5 groups be-
cause the average repurposing possibility score of each
group is decreasing in that order.
Established Disease and Drug Vectors
In our experiment, we first establish all of the clini-
cal diseases and drug vectors. All the clinical disease
sign vectors are represented in Table S2, and all the
clinical drug effect vectors are represented in Table
S3.
Then, we calculate the repurposing possibility score
of 392 kinds of drugs on six disease conditions (asthma,
coronary heart disease, congestive heart failure, heart
attack, type 2 diabetes and stroke). The repurposing
possibility score of each drug-disease pair is listed in
Table S4. We also transform the table into a heat
map Figure 4 to vividly present the repurposing possi-
bility score. Due to page limitation, we just present the
drugs that have an influence on any of the 6 diseases
in our experiment (153 kinds of drugs). The complete
heat map can be is in Figure S3. Then we perform
validations on our prediction for each of the six dis-
ease conditions. Each of the six disease conditions has
enough sample size which can make our validation re-
sult more confident. We extract a list of drugs from
the drug indication information resources for each of
the six disease conditions provided by SIDER. All of
the drugs in the six lists are known to treat the six
disease conditions respectively, so we assume them as
the ground truth and further compare them with our
prediction.
Evaluation of Known Drug-disease Associations
The results of the prediction at K for 6 disease condi-
tions are shown in Figure 2. The figure demonstrates
the precision of our prediction at K ∈ {5, 10, 15, 20}.
For type 2 diabetes, stroke, heart attack and conges-
tive heart failure, it is clear that most of the drugs can
be mapped into the ground truth(SIDER drug list)
when the K is small, the precisions of all the four
disease conditions in the figure are greater than or
equal to 0.8 when K = 5, their precision will decrease
with the increase of K. However, the results of asthma
and coronary heart disease were not as expected. For
coronary heart disease, there is not so many known
drug-disease pair in SIDER, which could be a reason
for the low precision of this disease condition. Some
of the clinical variables, like cholesterol, LDL (low-
density lipoprotein), HDL (high-density lipoprotein)
and triglycerides are more salient features than other
clinical variables. So, our analysis for the disease con-
dition which does not have a strong correlation with
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Figure 2 Top K precision of each disease condition demonstrates the proportion of known drug-disease pairs among the top K
ranking drugs in our prediction list. This prediction list is ranked by repurposing possibility score.
Figure 3 Fold-enrichment result of each disease condition, we divide the drug-disease pair into 5 groups with the descending order of
average repurposing possibility score. So, the negative linear relations between the group order and FE score indicate the positive
relationship between the average repurposing possibility score. It shows our scoring function is useful in finding the drugs which have
a therapeutic effect on target diseases.
these clinical variables could have low precision. Apart from those known treatments of each target disease
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that can be found in the ground truth, there could be
some unknown drug candidates which are likely to be
the treatment of target disease.
The results of the FE test are shown in Figure 3.
As we can see, there is a negative linear relationship
between the FE score and the group order. Since the
average FE test score is decreasing with the ascending
order of groups, so there is a positive linear relationship
between FE score and average repurposing possibility
score. The result in Figure 3 shows that all 6 disease
conditions demonstrate a negative linear relationship
between their FE score and group order. Therefore,
our scoring function is proven to be reasonable.
Case Study and Explainability
Having presented that our model successfully identi-
fied known associations between drugs and diseases,
we further demonstrate the explainability of our model
via corresponding complementarity between labora-
tory tests of drug effect vectors and disease sign vec-
tors. To exemplify this, we select 5 drug-disease associ-
ation pairs (i.e., Type 2 diabetes-Clopidogrel hydrogen
sulfate, Type 2 diabetes-Doxycycline hyclate, Coro-
nary heart disease-Alendronate sodium, Congestive
heart failure-Alendronate sodium and Heart attack-
Alendronate sodium). For a given disease, the selected
drugs are in its top-20 predicted list but not have been
indicated as the treatment. In order to vividly com-
pare the clinical vectors of the drug candidates and
the corresponding disease, we present the clinical vari-
ables which contribute to their repurposing possibility
score in Table 1. All the detailed clinical vectors can be
found in Table S2 and Table S3 of Supplementary
Materials. Combining the clinical disease vectors with
clinical drug effect vectors, we can analyze why the
drug candidates we select are potential treatments for
corresponding disease conditions from the standpoint
of clinical variables included in our experiment.
In the case of type 2 diabetes, we found that clopido-
grel hydrogen sulfate could have a therapeutic effect on
type 2 diabetes and Doxycycline Hyclate. Clopidogrel
hydrogen sulfate is an antiplatelet medication and can
be used to reduce the risk of myocardial infarction and
stroke [21]. A study reported that clopidogrel will alle-
viate insulin resistance and improve glycemic control
in type 2 diabetic patients [22], which is an important
cause of insulin resistance. From the clinical drug effect
vector of clopidogrel and clinical disease sign vector of
type 2 diabetes, we can see clopidogrel and type 2 di-
abetes have the opposite effect on the cholesterol and
LDL level. Lower cholesterol and LDL levels are bio-
logical markers of good glycaemic control [23], which
is also corresponding to the literature study. Doxycy-
cline Hyclate is an antibiotic which is primarily used
to treat a wide range of bacterial infections. From the
clinical vectors of Doxycycline and type 2 diabetes, we
can see they have the opposite effect on the serum glu-
cose level. High fasting blood glucose level is a common
biological marker among type 2 diabetes patients. This
finding is supported by a medical study that doxycy-
cline can improve insulin resistance and fasting blood
glucose level [24]. The analysis based on the opposite
effect of type 2 diabetes and clopidogrel proves our
prediction is reasonable, clopidogrel and doxycycline
may be used as treatments for type 2 diabetes .
Alendronate sodium is usually used to treat osteo-
porosis [25]. We found it can potentially have a thera-
peutic effect on cardiovascular disease, including con-
gestive heart failure, heart attack and coronary heart
disease. Experiments show that alendronate can in-
duce significantly lower cardiovascular mortality and
reduce the risk of cardiovascular incidents [26]. A pos-
sible explanation given by this study is that bone
and cardiovascular remodeling share some biological
markers. From the clinical drug effect vectors of al-
endronate, we can see alendronate can lower alkaline
phosphatase (ALP) and elevate the HDL level. Re-
searches show that ALP can catalyze the inhibitor of
vascular calcification, thus high-level ALP may lead to
vascular hardening and promotes the atherosclerotic
process [27]. On the other hand, HDL will promote re-
verse cholesterol transport, which could reduce the risk
of cardiovascular events [28]. Thus, it seems possible
that alendronate could be repurposed as a treatment
for cardiovascular disease.
Highly related drugs and diseases
In Fig. 4, we demonstrate part of the repurposing pos-
sibility scores in the form of heat map. To further dig-
ging the relation within different drugs or diseases,
we use bi-clustering algorithm to do a clustering for
the drugs and diseases in Fig. 4. Bi-clustering is a
data mining technology that simultaneous clustering
of both row and column sets in a data matrix [29].
Given an m× n, bi-clustering algorithm will generate
new m× n matrix that a subset of rows which exhibit
similar behavior across a subset of columns, or vice
versa. In our work, we use bi-clustering algorithm to
find different drugs with similar effect on some a dis-
ease and different diseases which can be treated with
same kind of drug. The clustering result is plotted in
Fig. 5. As shown in Fig. 5, type 2 diabetes has a strong
correlation with heart diseases and stroke. We can also
find many drugs that can decrease blood lipid or sugar
level have a therapy effect on those diseases. In the
further, these findings can help to find potential drug-
disease pairs.
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Table 1 This table presents the selected previously unknown drug-disease pairs predicted by our method, we just show the clinical
variables that contribute to the final repurposing possibility of each drug-disease pair in the table.
Laboratory Test Alkaline Phosphatase Cholesterol Glucose HDL LDL Triglycerides
Disease Type 2 Diabetes ↓ ↑ ↑ ↓ ↑ ↑
Drug Clopidogrel Hydrogen Sulfate - ↓ - - ↓ -
Disease Type 2 Diabetes ↓ ↑ ↑ ↓ ↑ ↑
Drug Doxycycline Hyclate - - ↓ - - -
Disease Coronary Heart Disease ↑ ↑ ↑ ↓ ↑ ↑
Drug Alendronate Sodium ↓ - - ↑ - -
Disease Congestive Heart Failure ↑ ↑ ↑ ↓ ↑ ↑
Drug Alendronate Sodium ↓ - - ↑ - -
Disease Heart Attack ↑ ↑ ↑ ↓ ↑ ↑
Drug Alendronate Sodium ↓ - - ↑ - -
Limitations and further work
The verification results above show that our frame-
work may identify some potential drug indications and
thus help researchers find novel uses of existing drugs.
However, our framework still has some limitations and
space to improve.
First of all, we only include 6 kinds of diseases and
392 kinds of drugs in the our work. Actually, there
are some other disease conditions and drugs that can
be found in NHANES and EHR dataset. The reason
we just include a part of drugs and diseases is that
many of them have a small sample size so that we can
not get a reliable result from them. To guarantee the
results we get from the dataset are reliable enough, the
sample size of each drug and disease that included in
this work is larger than 1000. Due to this threshold,
the experiments are conducted on 6 diseases conditions
and 392 drugs, but the results we get are reliable and
robust. In the future, we can include more drug-disease
pairs with a large-scaled dataset.
The second limitation is the clinical variables in-
volved in the experiment. Hundreds of clinical vari-
ables (laboratory tests) can be found in the NHANES
dataset, but we still need to match them with the clin-
ical variables in the EHR dataset. However, 35 kinds of
clinical variables cannot completely reflect the human
physiological activity, so it would be also addressed
if we have a larger EHR dataset that contains more
clinical variables.
Conclusion
In this paper, we establish a drug repurposing compu-
tational framework by using the electronic clinical in-
formation from the National Health and Nutrition Ex-
amination Survey (NHANES) and Electronic Health
Records(EHR). We consider both of the opposite and
same expressions between clinical disease sign vector
and clinical drug effect vector in each drug-disease pair
to calculate the repurposing possibility score. Our in-
ferences of the novel use for different drugs are based
on their repurposing possibility score with different
disease conditions. We verify our predictions by fold-
enrichment test and top K precision. Then, we further
prove the feasibility of our model by doing a literature
analysis of our prediction result. The result shows that
our framework can not only retrieve the known indi-
cations of existing drugs but also find the previously
unknown indications of existing drugs. So our frame-
work can be potentially used in the drug repurposing
tasks.
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Additional Files
Table S1 — Laboratory Test List
This table includes the name of 35 kinds of laboratory test involved in our
experiments and their corresponding NHANES code. (Supplementary
Data.pdf)
Table S2 — Clinical Disease Sign Vector
This table presents 6 kinds of disease conditions involved in our experiment
and their influences on the 35 kinds of laboratory tests. (DiseaseVector.csv)
Table S3 — Clinical Drug Effect Vector
This table presents 392 kinds of existing drugs or drug combinations
involved in our experiment and their influences on the 35 kinds of
laboratory tests. (DrugVector.csv)
Table S4 — Repurposing Possibility Score
This table include the repurposing possibility score of each drug-disease
pair in our experiment. (Repurposing Possibility Score.csv)
Figure S1 — Disease Clinical Variable Statistics
The figure present number of diseases will increase (Up) or decrease
(Down) the level of each clinical variables. X-axis is the name of each
clinical variable, Y-axis is the number diseases. Blue bar stands for the ”Up”
relation, red bar stands for the ”Down” relation. (Supplementary Data.pdf)
Figure S2 — Drug Clinical Variable Statistics
The number of drugs will increase (Up) or decrease (Down) the level of
each clinical variables. X-axis is the name of each clinical variable, Y-axis is
the number diseases. Blue bar stands for the ”Up” relation, red bar stands
for the ”Down” relation. (Supplementary Data.pdf)
Figure S3 — Detailed Drug-Disease Heat Map
We transform the repurposing possibility score table into heat map and
present it in this figure. This version includes the repurposing possibility
scores of all the drug-disease pair. (HeatMap(full).png)
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Figure 4 Heat map of drug-disease repurposing possibility
scores. X-axis stands for the 6 disease conditions and Y-axis is
the name of the 153 drugs that have an influence on any of
the diseases involved in our experiment. The color bar above
the heat map annotates the scores that different colors in the
heat map stand for.
Figure 5 The heat map after bi-clustering, X-axis stands for
the 6 disease conditions and Y-axis is the name of the 153
drugs that have an influence on any of the diseases involved in
our experiment. The color bar above the heat map annotates
the scores that different colors in the heat map stand for.
